ARD1抗结直肠癌细胞机理研究进展

Research Progress on The Mechanism of ARDl Resistance The Colorectal Cancer Cell

目的总结近年来人停滞缺陷蛋白1(human arrest defective 1,h ARD1)蛋白在结直肠癌中的发病机理及诊疗过程中的最新研究进展。方法通过对CNKI、Pub Med等数据库文献进行检索,对有关ARDl在结直肠癌发生、发展、诊断、治疗等过程中的文献加以综述。结果 ARD1具有抗结直肠癌的作用,ARD1可以抑制结直肠癌细胞的增殖,促进其凋亡;此外,在细胞水平上能够提高结直肠癌细胞对抗癌药物的敏感性。治疗上主要是通过诱导癌细胞凋亡或(和)降低癌细胞的增殖能力,从而延缓疾病的进程。目前,ARD1在结直肠癌的研究还处于动物实验阶段,还不能直接进入临床。结论 ARDl抗结直肠癌细胞机理研究逐渐成为研究热点,随着动物研究的深入和推广,有希望为诊断和治疗结直肠癌提供全新的治疗理念和治疗措施。

Objective To summarize the recent research progress on pathogenesis of human arrest defective 1（ARD1） protein in colorectal cancer and treatment process. Methods Searched the related literatures from the databases such as CNKI, Pub Med and so on, the relevant ARD1 in the development, diagnosis and treatment of colorectal cancer were reviewed. Results ARD1 has effect of anti colorectal cancer, it can inhibit the proliferation and promote apoptosis of colorectal cancer cells, and improve the sensitivity of colorectal cancer cells to anticancer drugs at the cellular level. The treatment is mainly through the induction of cancer cell apoptosis or（and） decreased the proliferation ability of cancer cells, thus delaying the disease process. However, it is still in the research stage of animal experiments,which can not be directly applied to clinical practice. Conciusions ARDl study on the mechanism of anti colorectal cancer cells has become the focus of research with animal research and promotion, and provide new therapy concepts and measures for diagnosis and treatment of colorectal cancer.